Lentinan inhibits colorectal cancer stemness by binding CD133 and suppressing the CD133/p85/p-AKT signaling axis

Yan Liu, Lufei Yang, Junxi Liu, Zihao He, Jingyi Wang, Yu Zhang, Kaiping Wang, Jinglin Wang · 2025

Read Lentinan inhibits colorectal cancer stemness by binding CD133 and suppressing the CD133/p85/p-AKT signaling axis by Yan Liu, Lufei Yang, Junxi Liu, Zihao He, Jingyi Wang, Yu Zhang, Kaiping Wang, Jinglin Wang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12727974.txt.

Description

Yan Liu and co-authors published a study in 2025 on a mushroom compound and colon cancer. Colon cancer often comes back and resists drugs, in part due to stem-like cancer cells. Such cells can regrow a tumor after treatment. The compound, drawn from a fungus, is known to boost the immune system.

The team tested the compound on two colon cancer cell lines in the lab. It slowed cell growth and cut the stem-like traits of the cells. Tests showed the compound binds a surface protein found on these stem-like cells. By binding there, it shuts down a growth signal chain inside the cell. The authors say plant and fungus sugars like this one merit more study as cancer drugs.

Catalog record

CREATORYan Liu, Lufei Yang, Junxi Liu, Zihao He, Jingyi Wang, Yu Zhang, Kaiping Wang, Jinglin Wang
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE46 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12727974

Browse the full library · About the Tower of Babel